N-desmethyl Olanzapine
Code | Size | Price |
---|
TAR-T35716-1mg | 1mg | £99.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T35716-5mg | 5mg | £209.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T35716-10mg | 10mg | £272.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T35716-25mg | 25mg | £499.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T35716-50mg | 50mg | £688.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
N-desmethyl Olanzapine is a major metabolite of the atypical antipsychotic agent olanzapine .1,2N-desmethyl Olanzapine is formedviaoxidative metabolism of olanzapine by the cytochrome 450 (CYP) isoform CYP1A2.1
CAS:
161696-76-0
Formula:
C16H18N4S
Molecular Weight:
298.41
Pathway:
Metabolism
Purity:
0.98
SMILES:
Cc1cc2c(Nc3ccccc3N=C2N2CCNCC2)s1
Target:
Drug Metabolite|P450
References
Chiu JA, et al. Analysis and pharmacokinetics of olanzapine (LY170053) and two metabolites in rat plasma using reversed-phase HPLC with electrochemical detection. J Pharm Biomed Anal. 1996;14(5):609-615.
Ring BJ, et al. Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J Pharmacol Exp Ther. 1996;276(2):658-666.
Skogh E, et al. Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting. Ther Drug Monit. 2002;24(4):518-526.